Stay updated on Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page footer now displays Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision label on the page updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check59 days agoChange DetectedThe update is a minor metadata revision (Revision: v3.4.1 added; Revision: v3.4.0 removed) with no changes to study data or page content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check81 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check103 days agoChange DetectedAdded a dedicated Locations section listing study sites in Georgia, Massachusetts, and New York (Atlanta/Emory, Boston/MGH, New York/NYU Perlmutter) and updated the record to revision v3.3.3. The HHS Vulnerability Disclosure footer link was removed.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenalidomide in Lymphoma Clinical Trial page.